Lead Product(s) : AGA111
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Angitia Shares AGA111 Phase 1/2 Data at 2025 AAOS Meeting
Details : AGA111 is a recombinant human bone morphogenic protein 6 (rhBMP6) product in clinical development to promote bone fusion & functional outcomes in patients undergoing spinal fusion procedures.
Product Name : AGA111
Product Type : Protein
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : AGA111
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Spine BioPharma
Deal Size : $155.0 million
Deal Type : Agreement
Spine BioPharma Signs with Ensol BioSciences to Expand Indications for SB-01 Injection
Details : Spine BioPharma acquired the right to develop and commercialize SB-01, excluding Korea. It is being evaluated for the treatment of pain-related disability, associated with Degenerative Disc Disease.
Product Name : SB-01
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Spine BioPharma
Deal Size : $155.0 million
Deal Type : Agreement
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Spine BioPharma Completes Enrollment for Phase 3 Trial of SB-01 for Chronic Low Back Pain
Details : SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. It is being developed for chronic low back pain in degenerative disc disease.
Product Name : SB-01
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2024
Lead Product(s) : SB-01
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone
Details : Hyalofast is a highly differentiated, single-stage, bone preserving, hyaluronic acid matrix, which is intended to support the entrapment of mesenchymal stem cells obtained from autologous bone marrow aspirate concentrate for the repair of chondral and os...
Product Name : Hyalofast
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2023
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : gMSC1
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Chugai Pharmaceutical
Deal Size : Undisclosed
Deal Type : Termination
Details : Upon termination of the Agreement, all domestic and foreign rights with respect to guaranteed Mesenchymal Stem Cell 1 (gMSC®1), a regenerative cellular medicine for chondrogenesis in the knee, granted to Chugai from TWOCELLS will be returned to TWOCELLS...
Product Name : gMSC1
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 13, 2023
Lead Product(s) : gMSC1
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Chugai Pharmaceutical
Deal Size : Undisclosed
Deal Type : Termination